PRINCETON, NJ / ACCESSWIRE / February 1, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has ...
IND-enabling safety evaluations of PolyTope® TATX-03, executed under Good Laboratory Practice (GLP) standards and regulatory guidelines, revealed no in vivo adverse effects during histopathological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results